Summary of COVID-19 medicines guidance: Policy, Commissioning and Managerial

Laura Kearney, Regional Principal Medicines Information Pharmacist, Midlands and East Medicines Advice Service (Midlands site) & UK Drugs in Lactation Advisory ServicePublished Last updated See all updates

This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to Policy and Commissioning during coronavirus pandemic.

Our advice is constantly reviewed as the pandemic situation evolves.

Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.

To see our professional guidance summaries for other clinical areas, click here

Advice in this area includes:

 

NHS England/NHS Improvement: Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and over) version 3 

Last updated 15 June 2021

  • This policy sets out the interim clinical commissioning position for the use of remdesivir for patients with COVID-19.

 

NHS England/NHS Improvement: Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic

Last updated November 2020

  • This guidance for clinicians and managers outlines practical information about delivering remote consultations and other ways of remote working in secondary care
  • It includes detailed guidance on how to conduct the consultation itself, and exception criteria.

 

HM Government: Medicines and Healthcare products Regulatory Agency (MHRA) guidance on coronavirus

Last updated 22 June 2021

Summary

  • Repository of guidance and information for industry, healthcare professionals and patients covering the coronavirus (COVID-19) pandemic.
  • Includes latest clinical trial and vaccination information.
  • Includes guidance on relevant medicine and medical devices.

 

HM Government: COVID-19: guidance for health professionals

Last updated 15 March 2021

  • This is a repository of a number of guidelines regarding the assessment and management of suspected and confirmed UK cases.
  • It includes general guidance as well as guidance on infection prevention and control, adult social care, sampling and laboratory diagnostics, and surveillance reports.

 

HM Government: Covid-19: investigation and initial clinical management of possible cases

Last updated 14 December 2020

  • This generalised guidance is for clinicians clinically assessing potential COVID-19 cases.
  • It describes the definition of a COVID-19 infection, when testing should be considered, and actions to take if a case requires admission to hospital.

 

HM Government: Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19

Last updated 3 September 2021

  • This guidance defines those people who are classed as clinically extremely vulnerable, including young people.
  • It is written for these patient groups, their family, friends and carers and is available in a number of translations and versions, including easy read.
  • It provides examples and advice about how to minimise risk.
  • Guidance is updated in-line with any national or regional restrictions.

 

HM Government: Medicines and Healthcare products Regulatory Agency (MHRA) Coronavirus Yellow Card reporting site

Summary

  • Healthcare professionals, patients and carers can report all suspected adverse drug reactions associated with any medicines used in patients with confirmed or suspected COVID-19.
  • This includes medicines to manage long term or pre-existing conditions and medicines being used off-label and in clinical trials.
  • The site has been developed as part of the MHRA’s work to protect the public through enhanced COVID-19 vigilance and in preparation for large-scale use of potential new or repurposed medicines, medical devices, diagnostic tests and future vaccines.
  • Reporting for incidents in clinical trials should also still be reported in line with trial protocols.

Change history

  1. Editorial amendments
  2. NHSE/: Interim Clinical Commissioning Policy for remdesivir (updated to version 3)
  1. HM Government: COVID-19: guidance for health professionals (link updated)
  1. NHSE/I: Community pharmacy in the context of coronavirus (COVID-19) (removed: guideline no longer available)
  2. NHSE/I: Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic (link updated)
  3. NHSE/I: Clinical Management of persons admitted to hospital with suspected COVID-19 infection (removed: guideline no longer available)
  4. HM Government: COVID-19: investigation and initial clinical management of possible cases (new guideline added)
  5. Editorial amendments
  1. Published